Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 104-113

  Jing, Yonghua ^a   Kim, Edward ^a   You, Min ^a   Pikalov, Andrei ^b   Tran, Quynh Van ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Bipolar; Cost; Mood stabilizer

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL BILLING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREMEDICATION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COSTS AND COST ANALYSIS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; RISPERIDONE; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67749130861     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903044092     Document Type: Article

References (23)

1. Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, Bryant-Comstock L. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19(5):483-495.
2. Hirschfeld RM, Vornik LA. Bipolar disorder-costs and comorbidity. Am J Manag Care 2005;11(3):S85-90.
3. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002;4(6):398-405. (Pubitemid 36041470)
4. APA. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4):1-50. (Pubitemid 34274969)
5. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002;24(10):1668-1676. (Pubitemid 35351851)
6. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999;50(10):1303-1308. (Pubitemid 29468533)
7. Guo JJ, Keck PE, Jr., Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006;67(7):1055-1061. (Pubitemid 44230876)
8. Guo JJ, Keck PE, Li H, Patel NC. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. Psychiatr Serv 2007;58(8):1073-1078. (Pubitemid 47290865)
9. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17(2):149-173; discussion 7.
10. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002;3(3):115-124. (Pubitemid 44121706)
11. Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry 2004;65 (Suppl 15): 21-24.
12. Vieta E, T'joen C, Mcquade RD, et al. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Am J Psychiatry 2008;165(10):1316-1325.
13. Kim E, Maclean R, Ammerman D, et al. Psychiatric hospitalization in bipolar disorder treated with mood stabilizer and adjunctive aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone: a retrospective claims database analysis. Clin Ther 2009;31(4):836-848.
14. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-144. (Pubitemid 29242574)
15. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18(2):153-171. (Pubitemid 29052479)
16. Bouckaert A, Crott R. The difference in mean costs as a pharmacoeconomic outcome variable: power considerations. Control Clin Trials 1997;18(1):58-64. (Pubitemid 27145448)
17. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161(4):692-699.
18. Fischer LR, Defor TA, Cooper S, et al. Pharmaceutical care and health care utilization in an HMO. Eff Clin Pract 2002;5(2):49-57.
19. Ash AS, Posner MA, Speckman J, et al. Using claims data to examine mortality trends following hospitalization for heart attack in Medicare. Health Serv Res 2003;38(5):1253-1262. (Pubitemid 37288496)
20. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20(12):1929-1936.
21. Fleurence RL, Dixon JM, Revicki DA. Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS Drugs 2006;20(7):591-599. (Pubitemid 43990535)
22. Fagiolini A, Chengappa KN, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008;22(8):655-669. (Pubitemid 351950097)
23. Kim E, Pikalov A, Tran Q, et al. Second-generation antipsychotics and hospitalization in bipolar disorder: a claims data analysis. Presented at the 60th Institute on Psychiatric Services, Chicago, IL, October 2-5, 2008.